Chronic hepatitis B (CH-B) is common in HIV-infected persons, and HIV accelerates the rate of hepatitis B-related liver disease progression. In the Multicenter AIDS Cohort Study (MACS), the risk of liver-related death was nearly 18 times higher in those coinfected with HIV-HBV compared to those with CH-B alone. Furthermore, the rate was two times higher after compared to before 1996, the time of the introduction of highly active antiretroviral therapy (HAART). These data support the need to study the effects of HAART on liver disease progression in HIV-HBV coinfected persons. This proposal investigates CH-B in HIV-infected persons receiving HAART in a cohort of HIV-HBV coinfected patients from the MACS and two well-characterized Australian cohorts, one in Melbourne and one in Sydney.
The first aim will test the hypothesis that long-term HAART active against HBV will alter the rate of HAART-related hepatotoxicity in HIV-HBV coinfected persons. We will determine the rates of hepatotoxicity over a five-year period following HAART initiation. In the second aim the magnitude and durability of HBV DNA suppression with a HBV active HAART regimen will be determined by prospectively following HBV DNA levels.
The third aim i s designed to study the evolution of resistance mutations that occur in persons who do not have a durable suppression of their HBV DNA with HBV-active HAART. The entire HBV genome will be sequenced at the time of relapse and then followed subsequently for the development of compensatory mutations. These mutant viruses will be tested for anti-viral drug sensitivity and replication competence.
These aims are integrated in the fourth aim, which tests the hypothesis that an effective HBV active HAART regimen will slow the rate of liver disease progression. In this aim, paired liver biopsies will be examined to determine the rates of liver disease progression and analyzed with respect to the ability to maintain a durable HBV DNA response, to the development of drug-resistant mutants, and to intrahepatic levels of HBV DNA and ccc DNA. Given the experience of the investigative team and the well-characterized cohorts involved, the results from this proposal will yield insights into the management of HIV-HBV co-infected patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI060449-05
Application #
7417839
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Sharp, Gerald B
Project Start
2004-05-01
Project End
2010-09-14
Budget Start
2008-05-01
Budget End
2010-09-14
Support Year
5
Fiscal Year
2008
Total Cost
$587,069
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Cabuang, Liza M; Shaw, Tim; Littlejohn, Margaret et al. (2012) In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection. J Med Virol 84:1166-76
Falade-Nwulia, Oluwaseun; Thio, Chloe L (2011) Liver disease, HIV and aging. Sex Health 8:512-20
Bhattacharya, Debika; Thio, Chloe L (2010) Review of hepatitis B therapeutics. Clin Infect Dis 51:1201-8
Locarnini, Stephen A; Yuen, Lilly (2010) Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 15:451-61
Thio, Chloe L (2010) Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther 15:487-91
Audsley, Jennifer; Littlejohn, Margaret; Yuen, Lilly et al. (2010) HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Virology 405:539-47
Price, Jennifer C; Thio, Chloe L (2010) Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 8:1002-12
Matthews, Gail V; Seaberg, Eric; Dore, Gregory J et al. (2009) Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 23:1707-15
Iser, David M; Lewin, Sharon R (2009) The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. Antivir Ther 14:155-64
Thio, Chloe L (2009) Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49:S138-45

Showing the most recent 10 out of 27 publications